Kennen MacKay
Stock Analyst at RBC Capital
(1.23)
# 2,511
Out of 4,415 analysts
33
Total ratings
35%
Success rate
5.87%
Average return
Main Sectors:
Top Industries:
15 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NUVB Nuvation Bio | Maintains: Outperform | $4 → $5 | $3.19 | +56.74% | 1 | Apr 17, 2024 | |
| AGIO Agios Pharmaceuticals | Maintains: Outperform | $40 → $42 | $32.80 | +28.05% | 3 | Jun 27, 2023 | |
| AMGN Amgen | Maintains: Sector Perform | $224 → $236 | $300.30 | -21.41% | 4 | Aug 5, 2022 | |
| EXEL Exelixis | Maintains: Outperform | n/a | $22.15 | - | 2 | Nov 3, 2021 | |
| ADCT ADC Therapeutics | Maintains: Outperform | n/a | $4.83 | - | 2 | Nov 3, 2021 | |
| LIFE aTyr Pharma | Initiates: Outperform | n/a | $1.70 | - | 1 | Oct 12, 2021 | |
| PRTA Prothena Corporation | Maintains: Outperform | n/a | $23.54 | - | 5 | Sep 30, 2021 | |
| PBYI Puma Biotechnology | Maintains: Sector Perform | n/a | $4.75 | - | 1 | Aug 6, 2021 | |
| BMRN BioMarin Pharmaceutical | Maintains: Sector Perform | n/a | $82.58 | - | 4 | Jul 29, 2021 | |
| NRIX Nurix Therapeutics | Initiates: Outperform | n/a | $14.16 | - | 1 | Apr 30, 2021 | |
| MESO Mesoblast | Initiates: Sector Perform | $48 | $7.96 | +503.39% | 1 | Oct 22, 2020 | |
| ABEO Abeona Therapeutics | Maintains: Outperform | n/a | $4.56 | - | 1 | Mar 18, 2020 | |
| MRUS Merus | Upgrades: Outperform | n/a | $48.73 | - | 3 | Apr 3, 2019 | |
| ANAB AnaptysBio | Downgrades: Sector Perform | n/a | $25.68 | - | 3 | Apr 4, 2018 | |
| KPTI Karyopharm Therapeutics | Initiates: Outperform | n/a | $1.10 | - | 1 | Sep 15, 2017 |
Nuvation Bio
Apr 17, 2024
Maintains: Outperform
Price Target: $4 → $5
Current: $3.19
Upside: +56.74%
Agios Pharmaceuticals
Jun 27, 2023
Maintains: Outperform
Price Target: $40 → $42
Current: $32.80
Upside: +28.05%
Amgen
Aug 5, 2022
Maintains: Sector Perform
Price Target: $224 → $236
Current: $300.30
Upside: -21.41%
Exelixis
Nov 3, 2021
Maintains: Outperform
Price Target: n/a
Current: $22.15
Upside: -
ADC Therapeutics
Nov 3, 2021
Maintains: Outperform
Price Target: n/a
Current: $4.83
Upside: -
aTyr Pharma
Oct 12, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.70
Upside: -
Prothena Corporation
Sep 30, 2021
Maintains: Outperform
Price Target: n/a
Current: $23.54
Upside: -
Puma Biotechnology
Aug 6, 2021
Maintains: Sector Perform
Price Target: n/a
Current: $4.75
Upside: -
BioMarin Pharmaceutical
Jul 29, 2021
Maintains: Sector Perform
Price Target: n/a
Current: $82.58
Upside: -
Nurix Therapeutics
Apr 30, 2021
Initiates: Outperform
Price Target: n/a
Current: $14.16
Upside: -
Mesoblast
Oct 22, 2020
Initiates: Sector Perform
Price Target: $48
Current: $7.96
Upside: +503.39%
Abeona Therapeutics
Mar 18, 2020
Maintains: Outperform
Price Target: n/a
Current: $4.56
Upside: -
Merus
Apr 3, 2019
Upgrades: Outperform
Price Target: n/a
Current: $48.73
Upside: -
AnaptysBio
Apr 4, 2018
Downgrades: Sector Perform
Price Target: n/a
Current: $25.68
Upside: -
Karyopharm Therapeutics
Sep 15, 2017
Initiates: Outperform
Price Target: n/a
Current: $1.10
Upside: -